Biotest Reports 4.5% Revenue Increase in First Nine Months of 2024

Biotest AG has announced a 4.5% rise in revenues, reaching €523 million in the first nine months of 2024. The increase is attributed to strong product sales and toll manufacturing, which grew by 13.7% to €414 million, supported by the success of Yimmugo®.

The company's Group EBIT saw a decline to €71.1 million from €125.4 million the previous year, largely due to decreased contributions from technology transfer and development services with Grifols, S.A.

Biotest has also submitted a marketing authorization application for Fibrinogen Concentrate (BT524) in Germany, Austria, and Spain, anticipating approval by mid-2025.

While EBIT guidance remains steady, revenue expectations have been adjusted due to potential risks from geopolitical conflicts and economic instability.